Health & Fitness
Health and Fitness
Health and Fitness
Sun, October 2, 2011
Sat, October 1, 2011
Fri, September 30, 2011
Thu, September 29, 2011
Celldex Therapeutics to Present at Second Annual aCancer Immunotherapy: A Long-Awaited Realitya Conference
NEEDHAM, Mass.--([ BUSINESS WIRE ])--Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the Company will present at the Second Annual aCancer Immunotherapy: A Long-Awaited Realitya Conference on Thursday, October 6, 2011 at the New York Academy of Medicine in New York City. The single-day conference event unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy.
Tibor Keler, Ph.D., Senior Vice President and Chief Scientific Officer, will participate in a panel discussion titled aAdjuvants in Immunotherapya at 10:30 am EDT. Additionally, Tom Davis, M.D., Senior Vice President and Chief Medical Officer, will provide an overview of the Companya™s Precision Targeted Immunotherapy Platform with a focus onrindopepimut (CDX-110) and critical factors in the validity of data for vaccines. Dr. Davis is scheduled to present at 12:00 noon EDT.
A corresponding live webcast of the Company presentation will be accessible by visiting the Events Calendar under the aNews & Eventsa section of the Celldex website at [ www.celldextherapeutics.com ].
To register or get more information, please visit the conference website at [ www.regonline.com/mdbpartners ].
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit [ http://www.celldextherapeutics.com ].
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:This release contains aforward-looking statementsa made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Companya™s strategic focus and the future development and commercialization (by Celldex and others) of rindopepimut (CDX-110), CDX-1307, CDX-011, CDX-1135 (formerly TP10), CDX-1401, CDX-1127, Belinostat and other products. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we plan to initiate in 2011; our ability to adapt APC Targeting TechnologyTM to develop new, safe and effective vaccines against oncology and infectious disease indications; our ability to successfully complete product research and further development of our programs; the uncertainties inherent in clinical testing; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage research and development efforts for multiple products at varying stages of development; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our limited cash reserves and our ability to obtain additional capital on acceptable terms, or at all; our ability to protect the Companya™s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Companya™s products; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Form 10-K for the fiscal year endedDecember 31, 2010, anditsForms 10-Q and 8-K.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
